Sabina Sangaletti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/979716/publications.pdf

Version: 2024-02-01

126708 110170 4,906 62 33 64 citations g-index h-index papers 69 69 69 8559 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Redirecting (i>In vivo (i>Elicited Tumor Infiltrating Macrophages and Dendritic Cells towards Tumor Rejection. Cancer Research, 2005, 65, 3437-3446.	0.4	498
2	Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood, 2012, 120, 3007-3018.	0.6	350
3	Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clinical Cancer Research, 2019, 25, 989-999.	3.2	315
4	Amino-Biphosphonate–Mediated MMP-9 Inhibition Breaks the Tumor-Bone Marrow Axis Responsible for Myeloid-Derived Suppressor Cell Expansion and Macrophage Infiltration in Tumor Stroma. Cancer Research, 2007, 67, 11438-11446.	0.4	310
5	Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer and Metastasis Reviews, 2010, 29, 295-307.	2.7	207
6	Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. Journal of Experimental Medicine, 2010, 207, 2931-2942.	4.2	175
7	Macrophage-Derived SPARC Bridges Tumor Cell-Extracellular Matrix Interactions toward Metastasis. Cancer Research, 2008, 68, 9050-9059.	0.4	174
8	RORC1 Regulates Tumor-Promoting "Emergency―Granulo-Monocytopoiesis. Cancer Cell, 2015, 28, 253-269.	7.7	154
9	The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment. Oncogene, 2019, 38, 3636-3650.	2.6	144
10	WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer. Oncogene, 2019, 38, 4047-4060.	2.6	137
11	Leukocyte, Rather than Tumor-produced SPARC, Determines Stroma and Collagen Type IV Deposition in Mammary Carcinoma. Journal of Experimental Medicine, 2003, 198, 1475-1485.	4.2	124
12	Mast Cell Targeting Hampers Prostate Adenocarcinoma Development but Promotes the Occurrence of Highly Malignant Neuroendocrine Cancers. Cancer Research, 2011, 71, 5987-5997.	0.4	124
13	Osteopontin Shapes Immunosuppression in the Metastatic Niche. Cancer Research, 2014, 74, 4706-4719.	0.4	110
14	Lipopolysaccharide or Whole Bacteria Block the Conversion of Inflammatory Monocytes into Dendritic Cells In Vivo. Journal of Experimental Medicine, 2003, 198, 1253-1263.	4.2	107
15	Defective Stromal Remodeling and Neutrophil Extracellular Traps in Lymphoid Tissues Favor the Transition from Autoimmunity to Lymphoma. Cancer Discovery, 2014, 4, 110-129.	7.7	100
16	Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity. Cell Reports, 2016, 17, 233-248.	2.9	84
17	Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs. Cancer Research, 2020, 80, 2874-2888.	0.4	81
18	Triggering CD40 on endothelial cells contributes to tumor growth. Journal of Experimental Medicine, 2006, 203, 2441-2450.	4.2	73

#	Article	IF	CITATIONS
19	ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells. Frontiers in Immunology, 2017, 8, 1918.	2.2	72
20	SPARC Oppositely Regulates Inflammation and Fibrosis in Bleomycin-Induced Lung Damage. American Journal of Pathology, 2011, 179, 3000-3010.	1.9	62
21	Accelerated dendritic-cell migration and T-cell priming in SPARC-deficient mice. Journal of Cell Science, 2005, 118, 3685-3694.	1.2	60
22	Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors. Clinical Cancer Research, 2017, 23, 5149-5161.	3.2	59
23	Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells. Cancer Research, 2019, 79, 1938-1951.	0.4	58
24	Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. Blood, 2012, 120, 3541-3554.	0.6	44
25	Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer. Cancer Immunology Research, 2018, 6, 552-565.	1.6	44
26	SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities. Frontiers in Immunology, 2019, 10, 1369.	2.2	44
27	The bone marrow stroma in hematological neoplasms—a guilty bystander. Nature Reviews Clinical Oncology, 2011, 8, 456-466.	12.5	42
28	Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity. Cell Death and Disease, 2013, 4, e920-e920.	2.7	41
29	SOCS2 Controls Proliferation and Stemness of Hematopoietic Cells under Stress Conditions and Its Deregulation Marks Unfavorable Acute Leukemias. Cancer Research, 2015, 75, 2387-2399.	0.4	39
30	Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma. Blood, 2014, 123, 1836-1849.	0.6	37
31	Common extracellular matrix regulation of myeloid cell activity in the bone marrow and tumor microenvironments. Cancer Immunology, Immunotherapy, 2017, 66, 1059-1067.	2.0	36
32	Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies. Oncolmmunology, 2014, 3, e28989.	2.1	34
33	SCD5â€induced oleic acid production reduces melanoma malignancy by intracellular retention of SPARC and cathepsin B. Journal of Pathology, 2015, 236, 315-325.	2.1	34
34	Matricellular proteins at the crossroad of inflammation and cancer. Cancer Letters, 2008, 267, 245-253.	3.2	33
35	DNA threads released by activated CD4 ⁺ T lymphocytes provide autocrine costimulation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8985-8994.	3.3	33
36	Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy. Cancers, 2019, 11, 624.	1.7	32

#	Article	IF	CITATIONS
37	Oncogene-Driven Intrinsic Inflammation Induces Leukocyte Production of Tumor Necrosis Factor That Critically Contributes to Mammary Carcinogenesis. Cancer Research, 2010, 70, 7764-7775.	0.4	31
38	Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis. Journal of Molecular Medicine, 2020, 98, 595-612.	1.7	31
39	The matricellular protein SPARC supports follicular dendritic cell networking toward Th17 responses. Journal of Autoimmunity, 2011, 37, 300-310.	3.0	29
40	Mast Cells Infiltrating Inflamed or Transformed Gut Alternatively Sustain Mucosal Healing or Tumor Growth. Cancer Research, 2015, 75, 3760-3770.	0.4	27
41	Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling. Cancer Research, 2017, 77, 3685-3699.	0.4	27
42	The good and bad of targeting cancer-associated extracellular matrix. Current Opinion in Pharmacology, 2017, 35, 75-82.	1.7	23
43	Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces. EBioMedicine, 2020, 61, 103055.	2.7	21
44	Matricellular proteins tune myeloid-derived suppressor cell recruitment and function in breast cancer. Journal of Leukocyte Biology, 2017, 102, 287-292.	1.5	20
45	Release of IFNÎ ³ by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells. Clinical Cancer Research, 2022, 28, 3141-3155.	3.2	20
46	Different requirements for \hat{l} ±-galactosylceramide and recombinant IL-12 antitumor activity in the treatment of C-26 colon carcinoma hepatic metastases. European Journal of Immunology, 2001, 31, 3101-3110.	1.6	19
47	Microenvironment-Centred Dynamics in Aggressive B-Cell Lymphomas. Advances in Hematology, 2012, 2012, 1-12.	0.6	15
48	Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence. Science Translational Medicine, 2018, 10 , .	5.8	13
49	Transcriptional profiles and stromal changes reveal bone marrow adaptation to early breast cancer in association with deregulated circulating microRNAs. Cancer Research, 2019, 80, canres.1425.2019.	0.4	13
50	Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments. Cellular Immunology, 2021, 362, 104301.	1.4	12
51	Antibodyâ€mediated blockade of JMJD6 interaction with collagen I exerts antifibrotic and antimetastatic activities. FASEB Journal, 2017, 31, 5356-5370.	0.2	10
52	Myeloid cell heterogeneity in lung cancer: implication for immunotherapy. Cancer Immunology, Immunotherapy, 2021, 70, 2429-2438.	2.0	10
53	SCD5-dependent inhibition of SPARC secretion hampers metastatic spreading and favors host immunity in a TNBC murine model. Oncogene, 2022, 41, 4055-4065.	2.6	10
54	Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers. Oncotarget, 2016, 7, 3905-3920.	0.8	9

#	Article	IF	CITATIONS
55	A combination of extracellular matrix―and interferonâ€associated signatures identifies highâ€grade breast cancers with poor prognosis. Molecular Oncology, 2021, 15, 1345-1357.	2.1	6
56	T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models. Cancer Immunology Research, 2021, 9, 825-837.	1.6	6
57	SPARC regulation of PMN clearance protects from pristane-induced lupus and rheumatoid arthritis. IScience, 2021, 24, 102510.	1.9	5
58	Neutrophil extracellular traps arm DC vaccination against NPM-mutant myeloproliferation. ELife, 2022, 11 , .	2.8	5
59	CIC-39Na reverses the thrombocytopenia that characterizes tubular aggregate myopathy. Blood Advances, 2022, 6, 4471-4484.	2.5	5
60	The ins and outs of osteopontin. Oncolmmunology, 2015, 4, e978711.	2.1	3
61	CD40 Activity on Mesenchymal Cells Negatively Regulates OX40L to Maintain Bone Marrow Immune Homeostasis Under Stress Conditions. Frontiers in Immunology, 2021, 12, 662048.	2.2	3
62	Impact of Immune Cell Heterogeneity on HER2+ Breast Cancer Prognosis and Response to Therapy. Cancers, 2021, 13, 6352.	1.7	2